|Bid||1.4100 x 4000|
|Ask||1.4100 x 800|
|Day's range||1.3000 - 1.5400|
|52-week range||0.5800 - 5.0000|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Today is shaping up negative for Clovis Oncology, Inc. ( NASDAQ:CLVS ) shareholders, with the analysts delivering a...
Shares of the cancer drugmaker Clovis Oncology (NASDAQ: CLVS) are under pressure yet again today. After this latest dip, Clovis' stock is down by over 46% for the year. The biotech released its 2022 second-quarter earnings report ahead of the opening bell Monday morning, and its latest financial results aren't a hit with shareholders.
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.